title: Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
authors.forename: I
authors.initials: I
authors.lastname: Cass
authors.forename: D Y
authors.initials: DY
authors.lastname: Kuo
authors.forename: A L
authors.initials: AL
authors.lastname: Fields
authors.forename: C D
authors.initials: CD
authors.lastname: Runowicz
authors.forename: G L
authors.initials: GL
authors.lastname: Goldberg
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan